Table 2.
Effects of SGI on pharmacokinetic parameter of tolbutamide (1.0 mg/kg).
| Parameters | BCG | Treatment Groups | |
|---|---|---|---|
| 7D-G | 14D-G | ||
| AUC(0–t)(mg/L·h) | 47.76 ± 15.23 | 73.87 ± 12.25 ** | 85.10 ± 13.42 ** |
| AUC(0–∞)(mg/L·h) | 53.39 ± 16.71 | 85.99 ± 13.26 ** | 106.40 ± 9.93 ** |
| MRT(0–t)(h) | 9.13 ± 1.55 | 11.52 ± 0.592 ** | 12.57 ± 0.35 ** |
| MRT(0–∞)(h) | 13.28 ± 3.71 | 17.68 ± 1.39 ** | 22.44 ± 4.44 ** |
| t1/2(h) | 9.77 ± 3.53 | 13.00 ± 0.87 | 16.43 ± 3.35 ** |
| CL(L/h/kg) | 0.02 ± 0.008 | 0.01 ± 0.002 ** | 0.01 ± 0.001 ** |
| Vd(L/kg) | 0.28 ± 0.14 | 0.22 ± 0.04 | 0.23 ± 0.06 |
BCG, blank control group (0.9% sodium chloride solution for 10 days); 7D-G, short-period group (5 mL/kg of SGI concentrated solution, iv, once daily for consecutive 7 days); 14D-G, long-period group (5 mL/kg of SGI concentrated solution, iv, once daily for consecutive 14 days). Values are represented as mean ± SD (n = 6). * p < 0.05 when compared with related parameters of model rats. ** p < 0.01 when compared with related parameters of model rats.